Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
On-demand/Mobile Minimize Pain Reduced Nausea Hydration Speed Recovery User Registration required for purchase
Theranostics 13 , 10591075 (2023)
Your glutathione levels depend on it
In summary, evidence across species suggests that under hypoglycemic or low-glucose conditions, myelin turnover can function analogously to adipose tissue mobilization, temporarily supplying energy to sustain axonal metabolism
10.1186/s13287-019-1382-y 15 KangJ
